blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3350188

EP3350188 - INHIBITORS OF TRYPTOPHAN DIOXYGENASES (IDO1 AND TDO) AND THEIR USE IN THERAPY [Right-click to bookmark this link]
StatusThe patent has been granted
Status updated on  09.02.2024
Database last updated on 22.08.2024
FormerGrant of patent is intended
Status updated on  23.05.2023
FormerExamination is in progress
Status updated on  26.11.2021
FormerRequest for examination was made
Status updated on  22.06.2018
FormerThe international publication has been made
Status updated on  04.03.2017
Most recent event   Tooltip02.08.2024Lapse of the patent in a contracting state
New state(s): LV		published on 04.09.2024 [2024/36]
Applicant(s)For all designated states
Auckland Uniservices Limited
Level 10, 49 Symonds Street
Auckland 1010 / NZ
[2023/44]
Former [2018/30]For all designated states
AUCKLAND UNISERVICES LIMITED
Level 10, 70 Symonds Street
Auckland / NZ
Inventor(s)01 / PALMER, Brian Desmond
9 Monet Grove
West Harbour
Auckland 0618 / NZ
02 / CHING, Lai-Ming
9 Monet Grove
West Harbour
Auckland 0618 / NZ
 [2018/30]
Representative(s)Mewburn Ellis LLP
Aurora Building
Counterslip
Bristol BS1 6BX / GB
[2024/11]
Former [2018/30]Watson, Robert James, et al
Mewburn Ellis LLP
City Tower
40 Basinghall Street
London EC2V 5DE / GB
Application number, filing date16839685.125.08.2016
[2018/30]
WO2016NZ50135
Priority number, dateNZ2014015711527.08.2015         Original published format: NZ 15711514
[2018/30]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2017034420
Date:02.03.2017
Language:EN
[2017/09]
Type: A1 Application with search report 
No.:EP3350188
Date:25.07.2018
Language:EN
The application published by WIPO in one of the EPO official languages on 02.03.2017 takes the place of the publication of the European patent application.
[2018/30]
Type: B1 Patent specification 
No.:EP3350188
Date:13.03.2024
Language:EN
[2024/11]
Search report(s)International search report - published on:AU02.03.2017
(Supplementary) European search report - dispatched on:EP01.03.2019
ClassificationIPC:C07D498/04, A61K31/437, A61P9/04, A61P13/12, A61P15/00, A61P25/00, A61P27/12, A61P29/00, A61P31/00, A61P35/00
[2018/30]
CPC:
C07D498/04 (EP,KR,US); A61K31/437 (EP,KR,US); A61K45/06 (KR,US);
A61P35/00 (EP,KR,US)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2018/30]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
MDNot yet paid
TitleGerman:INHIBITOREN VON TRYPTOPHANDIOXYGENASEN (IDO1 UND TDO) UND DEREN VERWENDUNG IN DER THERAPIE[2018/30]
English:INHIBITORS OF TRYPTOPHAN DIOXYGENASES (IDO1 AND TDO) AND THEIR USE IN THERAPY[2018/30]
French:INHIBITEURS DES TRYPTOPHANE-DIOXYGÉNASES (IDO1 ET TDO) ET LEUR UTILISATION EN THÉRAPIE[2018/30]
Entry into regional phase14.02.2018National basic fee paid 
14.02.2018Search fee paid 
14.02.2018Designation fee(s) paid 
14.02.2018Examination fee paid 
Examination procedure05.02.2018Date on which the examining division has become responsible
14.02.2018Examination requested  [2018/30]
27.09.2019Amendment by applicant (claims and/or description)
25.11.2021Despatch of a communication from the examining division (Time limit: M06)
31.05.2022Reply to a communication from the examining division
20.09.2022Despatch of a communication from the examining division (Time limit: M04)
13.01.2023Reply to a communication from the examining division
24.05.2023Communication of intention to grant the patent
26.09.2023Fee for grant paid
26.09.2023Fee for publishing/printing paid
26.09.2023Receipt of the translation of the claim(s)
Fees paidRenewal fee
21.08.2018Renewal fee patent year 03
02.08.2019Renewal fee patent year 04
13.08.2020Renewal fee patent year 05
27.08.2021Renewal fee patent year 06
31.08.2022Renewal fee patent year 07
04.02.2024Renewal fee patent year 08
Penalty fee
Additional fee for renewal fee
31.08.202308   M06   Fee paid on   04.02.2024
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipBG13.03.2024
ES13.03.2024
FI13.03.2024
HR13.03.2024
LT13.03.2024
LV13.03.2024
NO13.06.2024
RS13.06.2024
GR14.06.2024
[2024/36]
Former [2024/35]BG13.03.2024
ES13.03.2024
FI13.03.2024
HR13.03.2024
LT13.03.2024
NO13.06.2024
RS13.06.2024
GR14.06.2024
Former [2024/34]BG13.03.2024
FI13.03.2024
HR13.03.2024
LT13.03.2024
NO13.06.2024
RS13.06.2024
GR14.06.2024
Former [2024/33]LT13.03.2024
NO13.06.2024
Documents cited:Search[A]EP1813606  (TAKEDA PHARMACEUTICAL [JP]) [A] 1-21 * the whole document * * in particular example 38 *;
 [A]WO2014186035  (CURADEV PHARMA PRIVATE LTD [IN]) [A] 1-21 * the whole document *;
 [E]RU2619120  (FED GOSUDARSTVENNOE BYUDZHETNOE OBRAZOVATELNOE UCHREZHDENIE VYSSHEGO PROFESSIONALNOGO OBRAZOVANIYA K [RU]) [E] 1-21* the whole document *;
 [A]  - MARK S. TICHENOR ET AL, "Heteroaryl urea inhibitors of fatty acid amide hydrolase: Structure-mutagenicity relationships for arylamine metabolites", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, AMSTERDAM, NL, (20121201), vol. 22, no. 24, doi:10.1016/j.bmcl.2012.10.076, ISSN 0960-894X, pages 7357 - 7362, XP055477985 [A] 1-21 * the whole document * * in particular Scheme 2 on page 7359, compounds 18m to 18p *

DOI:   http://dx.doi.org/10.1016/j.bmcl.2012.10.076
International search[A]WO2005089753  (JANSSEN PHARMACEUTICA NV [BE], et al) [A] 1-80 * Page 2 lines 22-28, page 2 line 30 - page 4 line 13, page 10 line 10 - page 11 line 21, page 20 Scheme 2, Claims 1 and 9. *;
 [A]US2008176915  (MERLA BEATRIX [DE], et al) [A] 1-80 * Paragraphs [0006]-[0026], Claims 1, 20 and 21. *;
 [A]US2008312301  (MERLA BEATRIX [DE], et al) [A] 1-80 * Paragraphs [0005]-[0044], Claims 35 and 69-72. *;
 [PA]WO2016024233  (AUCKLAND UNISERVICES LTD [NZ], et al) [PA] 1-80* Page 2 line 19 - page 5 line 13, page 6 lines 18-32, Examples, Claims 1, 23-26, 28, 31, 34-36 and 39. *;
 [X]  - POREBA, K. et al., "Synthesis and antibacterial activity of new sulfonamide isoxazolo[5,4- b]pyridine derivatives", Acta Poloniae Pharmaceutica - Drug Research, (20150000), vol. 72, no. 4, pages 727 - 735, XP055515617 [X] 1, 2, 5, 6, 14-17, 31-33 and 67-80 * . Page 728 left column line 29 - page 729 left column line 11, page 729 right column line 35 - page 730 left column line 43, page 731 left column line 22 - right column line 2 Section In vitro antibacterial activity, page 731 right column lines 3-8 Section In vitro cytotoxicity, page 732 Table 2, pa *
 [X]  - POR?BA, K. et al., "Synthesis and Antiproliferative Activity In Vitro of New 3- Substituted Aminoisoxazolo[5,4-b]pyridines", Acta Poloniae Pharmaceutica - Drug Research, (20030000), vol. 60, no. 4, pages 293 - 301, XP 055366599 [X] 1, 2, 5, 6, 14-17, 31-33 and 67-78 * Pages 295-297 Table 1, page 299 Scheme 1, page 300 Table 2 and page 301 left column lines 5-9. *
by applicantWO2015082499
    - UYTTENHOVE et al., J. Nat. Med., (20030000), vol. 9, page 1269
    - ZHENG et al., J. Immunol., (20060000), vol. 177, page 5639
    - CADYSONO, Arch. Biochem. Biophys., (19910000), vol. 291, page 326
    - HOU et al., Cancer Res., (20070000), page 614
    - BRASTIANOS et al., J. Am. Chem. Soc., (20060000), vol. 128, page 16046
    - PEREIRA et al., J. Nat. Prod., (20060000), vol. 69, page 1496
    - KUMAR et al., J. Med. Chem., (20080000), vol. 51, page 1706
    - YUE et al., J. Med. Chem., (20090000), vol. 52, page 7364
    - NEWTON et al., J Clin Oncol., (20120000), vol. 30
    - Goodman and Gilman's The Pharmacological Basis of Therapeutics, McGraw-Hill, (20060000), pages 1225 - 1287
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.